<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic spontaneous urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarbjit Saini, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic spontaneous urticaria (CSU) is defined by the presence of recurrent urticaria (also called hives or wheals), angioedema, or both for a period of six weeks or longer [<a href="#rid1">1</a>]. There are several theories regarding the pathogenesis of CSU, none of which have been conclusively established. CSU is a self-limited disorder in most patients, with an average duration of disease of two to five years, although active CSU significantly impairs quality of life [<a href="#rid1">1</a>].</p><p>The clinical manifestations, epidemiology, diagnosis, theories of pathogenesis, and natural history of CSU will be reviewed here. The management of CSU is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education"</a> and  <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">"Chronic spontaneous urticaria: Treatment of refractory symptoms"</a>.)</p><p class="headingAnchor" id="H600237751"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The term "chronic spontaneous urticaria" (CSU) refers to patients with recurrent urticaria for six weeks or longer, as well as those with both urticaria and angioedema. Note that, since 2017, the international guidelines have included isolated idiopathic angioedema without urticaria in the definition of CSU, provided that other angioedema disorders (especially those mediated by bradykinin) have been excluded [<a href="#rid1">1,2</a>]. Therefore, CSU presents with an urticaria-predominant phenotype in approximately one-half of patients, a mixture of urticaria and angioedema in approximately 40 percent, and mainly angioedema in 10 percent. However, there are additional diagnostic considerations in patients with isolated angioedema, which are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/8105.html" rel="external">"An overview of angioedema: Clinical features, diagnosis, and management"</a>.)</p><p>The term "spontaneous" is included to differentiate CSU from several forms of inducible urticaria, which are hives triggered by physical stimuli, such as heat, cold, pressure applied to the skin, exercise, water, vibration, and sunlight. Physical urticaria is also called "inducible urticaria." Inducible urticaria syndromes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria"</a>.)</p><p>Other terms for CSU include "chronic idiopathic urticaria" and the general term "chronic urticaria." We favor the term "chronic spontaneous urticaria" over the others, although it is not as familiar to nonspecialists.</p><p class="headingAnchor" id="H1183511"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>At any given time, CSU affects up to 1 percent of the general population in the United States, and the prevalence is believed to be similar in other countries [<a href="#rid3">3-7</a>]. Both children and adults can develop CSU, although it is more common in adults. In adults, females are affected twice as often as males [<a href="#rid4">4,8-14</a>], and the condition most commonly begins in the third to fifth decades of life [<a href="#rid4">4,10,13</a>].</p><p class="headingAnchor" id="H1263753"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of CSU may be limited to the skin, although some patients report accompanying systemic symptoms.</p><p class="headingAnchor" id="H1177773262"><span class="h2">Cutaneous signs and symptoms</span></p><p class="headingAnchor" id="H3552480184"><span class="h3">Urticaria</span><span class="headingEndMark"> — </span>Urticarial lesions (also called hives or wheals) have three typical features [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An area of central swelling of various size, usually with surrounding erythema, although erythema may be difficult to appreciate on darker skin tones  (<a class="graphic graphic_picture graphicRef129552 graphicRef129553" href="/z/d/graphic/129552.html" rel="external">picture 1A-B</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An itching sensation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A fleeting time course for an individual lesion (usually 30 minutes to 24 hours), with the skin returning to normal without ecchymoses</p><p></p><p>Urticaria may be round, annular, or serpiginous  (<a class="graphic graphic_picture graphicRef89752 graphicRef129552 graphicRef72519 graphicRef129553 graphicRef63644 graphicRef81678 graphicRef77506" href="/z/d/graphic/89752.html" rel="external">picture 1A-G</a>). Any area of the body may be affected. Areas in which clothing compresses the skin (ie, under waistbands) or the skin rubs together (axillae) are sometimes affected more extensively. Patients with intense pruritus may occasionally injure their skin by scratching, resulting in excoriations (superficial erosions and crusts). The lesions may appear flattened if the patient is currently taking H1 antihistamines.</p><p>The pruritus of CSU may be severe enough to disrupt work, school, or sleep and is often most noticeable at night. Patients whose symptoms have resolved sometimes have difficulty describing urticarial lesions in a sufficiently detailed manner to assist in diagnosis. In this situation, showing patients photographs of urticaria and asking if the lesions looked similar can be helpful.</p><p>Individual lesions usually appear, possibly enlarge or merge, and then resolve within 24 hours. If the patient is having difficulty estimating how long an individual lesion lasts, they can trace a newly developed lesion with a pen and monitor the time to resolution. Lesions lasting longer than 24 hours and those that are painful or burning in nature or leave residual bruising are suggestive of a vasculitic process. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H2067994170"><span class="h3">Angioedema</span><span class="headingEndMark"> — </span>Angioedema, if present, is defined as episodic submucosal or subcutaneous swelling that is usually asymmetric in distribution and affects nondependent parts of the body, such as the lips, cheeks, periorbital areas of the face, extremities, and genitals [<a href="#rid15">15</a>]. It typically develops over minutes to hours and resolves gradually over one to three days, depending upon the initial severity. Affected areas typically feel slightly painful, numb, or tingling, rather than pruritic.</p><p>In contrast, angioedema involving the throat, tongue, or lips, <strong>without</strong> urticaria, should prompt consideration of drug-induced angioedema (such as that seen with angiotensin-converting enzyme inhibitors), hereditary angioedema, or acquired C1 inhibitor deficiency. Episodic abdominal pain due to angioedema of the intestinal mucosa is another distinguishing feature of these disorders. (See  <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">"ACE inhibitor-induced angioedema"</a> and  <a class="medical medical_review" href="/z/d/html/8099.html" rel="external">"An overview of angioedema: Pathogenesis and causes"</a>.)</p><p class="headingAnchor" id="H2408723869"><span class="h2">Systemic symptoms</span><span class="headingEndMark"> — </span>A subset of patients with CSU report systemic symptoms, including headache, fatigue, pain or swelling of joints, wheezing, flushing, gastrointestinal symptoms, and palpitations [<a href="#rid16">16,17</a>]. In a study of 155 CSU patients treated at a university allergy clinic, 103 reported systemic symptoms [<a href="#rid16">16</a>]. This subgroup had more severe and longer-lasting disease and significantly higher baseline tryptase levels compared with CSU patients without systemic symptoms (5.1 versus 3.9 ng/mL, respectively). Although there was likely some referral bias in this study toward patients with more severe disease, clinicians should inquire about systemic symptoms in patients with CSU.</p><p>Note that in patients with urticaria or angioedema accompanied by fever or objective evidence of joint inflammation, urticarial vasculitis should be considered. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3986177722"><span class="h2">Differences between children and adults</span><span class="headingEndMark"> — </span>Several differences between pediatric (&lt;18 years of age) and adult CSU were identified in a retrospective study of 162 children and 589 adults referred to an allergy/immunology clinic [<a href="#rid18">18</a>]. Pediatric patients, compared with adults, were less likely to experience angioedema (19 versus 60 percent), had a shorter average duration of symptoms (5 versus 12 months), and were more likely to improve with antihistamines, either at standard or higher doses. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Step 1'</a>.)</p><p class="headingAnchor" id="H2575461310"><span class="h1">BURDEN OF DISEASE</span><span class="headingEndMark"> — </span>CSU, as well as other forms of chronic urticaria, is extremely stressful for patients, causing decrements in daily function and days lost from work and school. The unpredictable nature of exacerbations is an additional source of frustration. In an early study, quality-of-life scores for patients with CSU were similar to those of patients with coronary artery disease, specifically with regard to fatigue, social isolation, and emotional reactions to the symptoms [<a href="#rid19">19</a>]. A patient's experience of having the disorder is provided separately. (See  <a class="medical medical_review" href="/z/d/html/131972.html" rel="external">"Patient perspective: Chronic urticaria"</a>.)</p><p>CSU is also costly for individual patients and for society, regardless of the health care system studied [<a href="#rid6">6,20-22</a>].</p><p class="headingAnchor" id="H94601710"><span class="h1">ASSOCIATED CONDITIONS</span><span class="headingEndMark"> — </span>CSU is associated with various atopic and autoimmune disorders. There is a possible association with malignancies, although data are conflicting.</p><p class="headingAnchor" id="H1915807115"><span class="h2">Allergic diseases</span><span class="headingEndMark"> — </span>Strong associations with atopic disorders, including food allergy, allergic rhinitis, chronic rhinosinusitis, atopic dermatitis, and asthma, were demonstrated in a large cohort study of over 1 million Israeli adolescents [<a href="#rid23">23</a>]. These associations were not seen in the adult population when studied by the same researchers. Instead, an association with autoimmune conditions was observed.</p><p class="headingAnchor" id="H94601717"><span class="h2">Autoimmune disorders</span><span class="headingEndMark"> — </span>Various autoimmune conditions are more prevalent among patients with CSU [<a href="#rid8">8,24-28</a>]. In the largest study, the prevalence of autoimmune disorders in nearly 13,000 patients with CSU was compared with over 10,000 control patients [<a href="#rid8">8</a>]. The following autoimmune disorders were more prevalent in patients with CSU: thyroid disorders, celiac disease, Sjögren's disease, systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes mellitus, with considerable variability between males and females. Antinuclear antibodies were also more prevalent than in the general population [<a href="#rid8">8</a>]. Among patients with CSU, an autoimmune disorder was more likely to be diagnosed in the decade after the onset of CSU rather than before it.</p><p class="headingAnchor" id="H557583"><span class="h3">Thyroid disorders</span><span class="headingEndMark"> — </span>In the larger study mentioned previously, hypothyroidism was diagnosed in 9.8 percent of CSU patients (versus 0.6 percent of controls) and hyperthyroidism in 2.6 percent (versus 0.5 percent of controls) [<a href="#rid8">8</a>]. A population-based Korean study found that individuals with autoimmune thyroid disease (Hashimoto thyroiditis and Graves' disease) had higher rates of CSU compared with controls (hazard ratio [HR] 1.5, 95% CI 1.3-1.7) [<a href="#rid29">29</a>].</p><p>Thyroid autoantibodies, specifically thyroid peroxidase antibodies or antimicrosomal antibodies, are more prevalent among patients with CSU (12 to 30 percent) compared with members of the general population (5 to 10 percent) [<a href="#rid9">9,30-33</a>]. However, the presence of thyroid autoantibodies does not necessarily correlate with abnormal thyroid function, and the majority of patients with CSU who have demonstrable thyroid autoantibodies have <strong>normal</strong> thyroid function [<a href="#rid31">31</a>]. The role of these autoantibodies in CSU in patients with normal thyroid function is not clear. Their presence may simply reflect an underlying tendency to develop autoantibodies [<a href="#rid26">26</a>]. However, even in the absence of hypo- or hyperthyroidism, patients with thyroid autoantibodies are often poorly responsive to standard therapies for CSU and have more persistent disease [<a href="#rid26">26,34</a>].</p><p>The pathogenesis of autoimmune thyroid disease is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7854.html" rel="external">"Pathogenesis of Hashimoto's thyroiditis (chronic autoimmune thyroiditis)"</a> and  <a class="medical medical_review" href="/z/d/html/7841.html" rel="external">"Pathogenesis of Graves' disease"</a>.)</p><p>Based upon the association between CSU and thyroid autoimmunity, several studies have examined the use of thyroid supplementation therapy in the treatment of CSU, with mixed results. These studies are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Patients with thyroid autoantibodies'</a>.)</p><p class="headingAnchor" id="H94601739"><span class="h2">Unclear association with malignancy</span><span class="headingEndMark"> — </span>The association between CSU (without vasculitis) and malignancy is unclear. Guidelines do not suggest that malignancy screening be performed in patients with CSU, unless indicated by specific abnormalities in the clinical history or physical exam or the presence of unintended weight loss [<a href="#rid1">1,35,36</a>]. Studies that support this approach include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>No increased risk of malignancy was found in a study of 1155 Swedish patients with CSU in which subjects were followed by academic dermatologists for an average of 8.2 years [<a href="#rid37">37</a>]. The incidence of malignant cancer during the period of observation was compared with the expected number of cancers from the Swedish Cancer Registry, yielding a relative risk (RR) of 0.88 (95% CI 0.61-1.12).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a systematic review of 6462 patients described in 29 studies, underlying diseases were detected as an underlying cause of CSU in only 105 patients (1.6 percent) [<a href="#rid24">24</a>]. Within this group, there were 60 cases of urticarial vasculitis, 17 patients with thyroid disease, 7 with lupus, and 16 with other connective tissue disorders. Three patients had a paraproteinemia, four had polycythemia vera, and five had various malignancies (breast cancer, acute myeloid leukemia, renal cell carcinoma, and two unidentified cancers). Therefore, few malignancies were detected in this review, and no one type of cancer predominated.</p><p></p><p>In contrast to the two studies above, a possible association was detected in a study of 12,720 Taiwanese patients with CSU [<a href="#rid38">38</a>]. In this cohort, subjects were identified as having CSU based upon the International Classification of Diseases (ICD) 9-CM code for urticaria, combined with use of an antihistamine for at least six months over a two-year period. Patients with coexisting allergic disorders that could require chronic antihistamines; patients receiving immunosuppressant drugs for any reason; and those with preexisting malignancies, rheumatoid arthritis, lupus erythematosus, or Sjögren's disease were excluded. The rate of malignancies diagnosed in this cohort over an average follow-up period of five years was compared with expected rates obtained from the Taiwan National Cancer Registry. The standardized incidence ratio for patients with CSU was 2.2 (95% CI 2.0-2.4). However, information about possible confounders (eg, smoking and alcohol use) was not included, and patients may not have been systematically evaluated for signs or symptoms of underlying disorders. In addition, the authors noted that there was no diagnostic code for urticarial vasculitis, which is known to be associated with malignancy, so this diagnosis would not have been easily distinguished from simple CSU. Therefore, this study may have overestimated cancer risk, although the association warrants further evaluation.</p><p>A case report and literature review described 26 patients in whom CSU preceded the diagnosis of a malignancy, usually by several months, and reported that treatment (ie, chemotherapy or surgical resection) led to resolution of the CSU in 88 percent of cases [<a href="#rid39">39</a>]. In three patients, return of urticaria signaled a recurrence of the malignancy.</p><p>Until the association between CSU and malignancy is better defined, it seems logical to continue to perform additional testing only if indicated by the patient's clinical history and physical exam.</p><p class="headingAnchor" id="H4"><span class="h1">EVALUATION AND DIAGNOSIS</span><span class="headingEndMark"> — </span>CSU is diagnosed clinically based upon the episodic and transient appearance of characteristic urticarial lesions, with or without angioedema, for a period of six weeks or longer. A detailed history and physical examination form the basis of the evaluation [<a href="#rid1">1,40-43</a>]. Several practice parameters have been published for the diagnosis of CSU [<a href="#rid1">1,35,36,44,45</a>]. The suggestions in this topic are consistent with them, although some variation exists among guidelines.</p><p class="headingAnchor" id="H5"><span class="h2">History</span><span class="headingEndMark"> — </span>The clinical history is an important element of the evaluation. The history should include the signs and symptoms associated with the lesions, duration of individual lesions, and accompanying angioedema. If signs and symptoms are consistent with CSU, then questioning should focus on identifying a possible underlying cause and on ensuring that the patient does not have evidence of a more serious systemic disease.</p><p class="bulletIndent1"><span class="glyph">●</span>To exclude a specific cause, clinicians should question patients about any newly administered drugs, including antibiotics, nonsteroidal antiinflammatory drugs (NSAIDs), and hormonal therapies [<a href="#rid46">46,47</a>]. Inquiries should be made about recent travel, infections, changes in health status, other atopic conditions, sexual history, and complete review of systems. No external cause can be identified in 80 to 90 percent of adults and children with recurrent urticaria persisting longer than six weeks once these known causes are excluded [<a href="#rid48">48-51</a>]. The various identifiable causes of urticaria are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be thoroughly questioned about signs and symptoms of systemic disease, such as fever, weight loss, arthralgias, arthritis, cold or heat sensitivity, abdominal pain, and bone pain [<a href="#rid25">25,52</a>]. Occasionally, urticaria or urticarial vasculitis will be a presenting feature of an underlying systemic disorder, such as systemic lupus erythematosus. Systemic diseases that can present with urticaria accompanied by other signs and symptoms and disorders that involve urticarial vasculitis are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria", section on 'Systemic disorders that may include urticaria'</a> and  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis", section on 'Associated conditions'</a>.)</p><p></p><p class="headingAnchor" id="H2907250978"><span class="h3">Aggravating factors</span><span class="headingEndMark"> — </span>Although not the sole cause of symptoms, certain factors aggravate CSU in a substantial subset of patients  (<a class="graphic graphic_table graphicRef98751" href="/z/d/graphic/98751.html" rel="external">table 1</a>). These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical factors</strong> – Some patients with CSU have some flares that are triggered by physical stimuli. As an example, heat (hot showers, extreme humidity) is a common trigger for many CSU patients, and tight clothing or straps can also aggravate symptoms. In contrast, patients in whom physical factors are the <strong>main</strong> trigger for symptoms are more appropriately diagnosed as having an inducible urticarial syndrome, such as cholinergic urticaria or delayed-pressure urticaria. Inducible urticarias are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">"Physical (inducible) forms of urticaria"</a> and  <a class="medical medical_review" href="/z/d/html/8102.html" rel="external">"Cold urticaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiinflammatory medications</strong> – NSAIDs worsen symptoms in 25 to 50 percent of patients with CSU [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stress</strong> – Patients often report more severe symptoms during periods of physical or psychologic stress [<a href="#rid54">54-61</a>]. However, evidence that psychosocial factors are in some way causative is lacking [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Variations in dietary habits and alcohol</strong> – Although food allergy is a rare cause of CSU, some patients will report that variations in diet, particularly rich meals or spicy foods, will aggravate symptoms. Alcohol also aggravates symptoms in some. The interactions between diet and CSU are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Dietary manipulations (controversial)'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Routine laboratory tests are unlikely to reveal abnormalities when the clinical history does not suggest an underlying allergic etiology or the presence of systemic disease [<a href="#rid24">24,35,63-66</a>]. Guidelines suggest initially obtaining a limited set of laboratories to screen for the systemic disorders that may involve urticaria [<a href="#rid2">2,44,67,68</a>]. The author and editors agree with limited testing and suggest the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>A complete blood count with differential</strong> – This is usually normal in patients with CSU [<a href="#rid69">69</a>]. Eosinopenia (ie, an absolute eosinophil count of &lt;50 cells/microL) was present in approximately 10 percent of patients with CSU in one large study of 1259 patients and was associated with basopenia, more severe disease, autoimmunity, and poor response to treatment with second-generation antihistamines and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid69">69</a>]. Eosinopenia is present in approximately 5 percent of the general population and has been linked to several disease states [<a href="#rid70">70</a>]. Eosinophil numbers should be assessed when the patient has not recently received glucocorticoids, which cause a rapid reduction in eosinophil counts.</p><p></p><p class="bulletIndent1">Eosinophilia should prompt evaluation for an atopic disorder or parasitic infection. (See  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p></p><p class="bulletIndent1">Basopenia has been associated with more severe disease [<a href="#rid71">71</a>]. (See <a class="local">'Cellular defects theory'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR)</strong> – Both tests are normal in the majority of cases of CSU, although an elevation of ESR of a few points is also common in uncomplicated CSU [<a href="#rid65">65</a>]. Significant elevations in ESR or CRP have been correlated with more severe disease, quality-of-life impairment, and nonresponse to antihistamines [<a href="#rid72">72</a>]. Such elevations should prompt further investigation for systemic diseases, such as autoimmune, rheumatologic, infectious, or neoplastic diseases. Such an evaluation may include measurement of antinuclear antibodies, cryoglobulins, hepatitis B and C serologies, total hemolytic complement, and a serum protein electrophoresis. (See  <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">"Acute phase reactants"</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid-stimulating hormone (TSH) level</strong> – Routine measurement of TSH was not endorsed by the 2017 or 2022 international guidelines [<a href="#rid1">1,2</a>]. However, some clinicians measure TSH in adults with CSU and/or obtain thyroid autoantibodies (antithyroglobulin, antimicrosomal antibodies, or both), while others do so only if the TSH level is abnormal [<a href="#rid73">73</a>]. Autoimmune thyroid disease is uncommon in children with CSU [<a href="#rid74">74</a>].</p><p></p><p>The utility of more extensive laboratory testing in patients with CSU was analyzed in the systematic review mentioned previously, which concluded that only ESR (or CRP) and complete blood count, with differential were useful screening tests. This review analyzed 29 studies (including 6462 patients) in which investigations for underlying medical disorders were performed [<a href="#rid24">24</a>]. Potentially causative internal diseases were identified in only 1.6 percent of patients, and there was no association between the number of tests ordered and the identification of an underlying disorder.</p><p class="headingAnchor" id="H1519355"><span class="h3">Investigational tests</span><span class="headingEndMark"> — </span>Investigational tests include the autologous serum skin test, various tests of basophil activation, and tests for autoantibodies to the immunoglobulin E (IgE) receptor or the Fc region of IgE [<a href="#rid1">1</a>]. These tests are discussed separately. (See <a class="local">'Theories of pathogenesis'</a> below.)</p><p class="headingAnchor" id="H2443482862"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of CSU can be made in a patient with characteristic skin lesions of urticaria and/or angioedema that appear and resolve repeatedly over a period of six weeks or longer. There should be no other signs of systemic illness, and laboratory testing is usually normal.</p><p>In patients with isolated angioedema, other angioedema disorders should be excluded. Measurement of complement component 4 (C4) is indicated because depressed C4 levels should prompt further evaluation for hereditary or acquired C1 inhibitor deficiency. In cases in which the history suggests a possible diagnosis of hereditary or acquired C1 inhibitor deficiency (ie, lack of response to antihistamines or positive family history), C1 inhibitor antigen and functional levels should also be measured. The evaluation of angioedema without urticaria is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8105.html" rel="external">"An overview of angioedema: Clinical features, diagnosis, and management", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Skin biopsy is not routinely needed for the diagnosis of CSU. However, a 3 mm punch biopsy of a newly formed lesion should be performed to exclude urticarial vasculitis in patients with one or more of the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Individual lesions that persist beyond 24 hours, are painful rather than pruritic, have accompanying petechial or purpuric characteristics, or leave residual pigmentation upon resolution [<a href="#rid43">43,75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An elevated CRP/ESR and/or systemic symptoms (eg, arthralgias, fever).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms that are unresponsive to appropriate doses of antihistamines. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'H1 antihistamines'</a>.)</p><p></p><p>The biopsy sample should be obtained from a fresh lesion. Patients receiving glucocorticoids may need to discontinue these medications for several days in order to allow new lesions to form. Biopsy specimens should be submitted in formalin for routine hematoxylin and eosin staining. In addition, if there is a strong clinical suspicion for urticarial vasculitis, a sample should be submitted in Michel's media or freshly snap frozen for direct immunofluorescence microscopy. Also consider testing for immunoglobulins in lesional skin when vasculitis is a consideration and in perilesional, noninvolved skin when considering autoimmune blistering disease.</p><p class="headingAnchor" id="H10"><span class="h3">Biopsy findings</span><span class="headingEndMark"> — </span>The biopsy findings of CSU vary somewhat among patients. Consistent features include interstitial edema with a perivascular mixed infiltrate consisting of lymphocytes, eosinophils, and, in some areas, a few neutrophils or basophils. Lymphocytes are generally CD4+ T lymphocytes. B lymphocytes are not usually seen [<a href="#rid15">15</a>]. Angioedema, if present, often shows a similar infiltrate and is characterized by more prominent edema of the interstitial tissues.</p><p>Neutrophil-predominant urticaria, without vasculitis, is a variant of CSU that is often refractory to standard pharmacologic treatments. The significance of neutrophil-predominant urticaria, in terms of preferred treatment or prognosis, is not known [<a href="#rid76">76</a>].</p><p>Findings that are <strong>not</strong> characteristic of CSU include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Several disorders in the differential diagnosis for CSU may also show a predominance of neutrophils, such as Schnitzler syndrome, delayed-pressure urticaria, and cryopyrin-associated periodic syndromes. Biopsies in these disorders may also mistakenly be interpreted as leukocytoclastic vasculitis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclasis should <strong>not</strong> be present in CSU. Leukocytoclasis is the fragmentation of neutrophils resulting in scattered nuclear fragments (nuclear dust) in the infiltrate, red blood cell extravasation within the lumen of affected vessels or in the interstitium, and fibrinoid degeneration of the endothelial cells resulting in a blunted vascular outline with fibrin deposits. If leukocytoclasis is found, the diagnosis of leukocytoclastic vasculitis and associated conditions should be considered. (See  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis", section on 'Histology'</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytoclasis accompanied by a dense cellular infiltrate consisting almost entirely of neutrophils, without evidence of vasculitis, should prompt evaluation for the rare disorder, neutrophilic urticarial dermatosis. (See  <a class="medical medical_review" href="/z/d/html/5571.html" rel="external">"Neutrophilic dermatoses"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">THEORIES OF PATHOGENESIS</span><span class="headingEndMark"> — </span>None of the theories of pathogenesis of CSU have been fully established, and we do not suggest routine performance of any of the tests mentioned in this section outside of research settings [<a href="#rid1">1,77</a>]. The best-developed hypotheses include the autoimmune theory [<a href="#rid78">78</a>], theories involving histamine-releasing factors, and the cellular defects theory.</p><p class="headingAnchor" id="H14"><span class="h2">Autoimmune theory</span><span class="headingEndMark"> — </span>The concept that CSU could represent an autoimmune disorder arose from the recognition that thyroid dysfunction and thyroid autoantibodies are more prevalent in patients with CSU [<a href="#rid8">8,25,30,31</a>]. This led to a search for autoantibodies and other serum factors that could be responsible for increased release of histamine from cutaneous mast cells and basophils. A European taskforce panel of CSU experts published a statement in 2013 concluding that there was persuasive but not conclusive evidence for the existence of autoimmune CSU as a specific disease entity [<a href="#rid79">79</a>]. The evidence suggesting that CSU may be an autoimmune disorder in some patients is reviewed above. (See <a class="local">'Autoimmune disorders'</a> above.)</p><p class="headingAnchor" id="H10997853"><span class="h3">The autologous serum skin test</span><span class="headingEndMark"> — </span>One area of investigation suggesting that CSU is an autoimmune disorder was introduced in the 1980s with the description of the autologous serum skin test (ASST) [<a href="#rid80">80</a>]. The ASST is proposed to provide an in vivo assay of mast cell activation induced by factors in the patient's serum. The ASST involves intradermal injection of the patient's own serum [<a href="#rid80">80,81</a>]. In preparation for this test, patients must refrain from taking antihistamines for three to seven days (depending upon the half-life of the specific drug), which can cause an exacerbation in symptoms.</p><p>In up to one-half of patients with CSU, the intradermal injection of serum produces a wheal-and-flare reaction (ie, area of cutaneous edema and erythema) at the site of injection within 30 minutes (note that the time to maximal reaction is longer than 15 minutes seen in allergen skin testing) [<a href="#rid82">82</a>]. In vitro tests of mast cell activation are lacking because mast cells are tissue-based cells that are not easily collected or cultured. (See  <a class="medical medical_review" href="/z/d/html/3979.html" rel="external">"Mast cells: Development, identification, and physiologic roles"</a>.)</p><p>The leading argument <strong>against</strong> the clinical significance of the ASST is that a positive test is not unique to patients with CSU [<a href="#rid83">83-85</a>]. In one study, positive ASSTs were found in 53 percent of patients with CSU, 20 percent of patients with nonallergic asthma/rhinitis, and 56 percent of healthy controls [<a href="#rid85">85</a>]. In addition, the positivity of the ASST persists in patients with CSU, even when the disorder is in clinical remission [<a href="#rid86">86,87</a>]. Finally, the ASST has not demonstrated clinical utility in identifying patients who respond differently to treatment or whose disease follows a different clinical course [<a href="#rid74">74,88-90</a>].  </p><p class="headingAnchor" id="H17"><span class="h3">Autoantibodies</span><span class="headingEndMark"> — </span>The sera of patients with CSU and positive ASSTs are capable of causing in vitro histamine release from basophils collected from control subjects [<a href="#rid80">80</a>]. It was therefore proposed that an autoantibody or other histamine-releasing factor was present in the serum of these patients.</p><p>At least two candidate autoantibodies have been identified [<a href="#rid81">81,86,91,92</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Human immunoglobulin G (IgG) molecules directed against the IgE receptor alpha subunit (anti-Fc-epsilon-R1-alpha)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human IgG molecules directed against the Fc region of IgE (anti-IgE)</p><p></p><p>The presence of IgG autoantibodies to the IgE receptor or the Fc region of IgE can be demonstrated in as many as 30 to 50 percent of children and adults with CSU [<a href="#rid15">15,79,93-97</a>]. These autoantibodies can trigger histamine release when incubated with normal basophils [<a href="#rid91">91</a>] and can activate mast cells, possibly through a mechanism involving complement [<a href="#rid15">15,51,98-102</a>]. Assays are commercially available for detecting anti-Fc-epsilon-RI-alpha antibodies (eg, the Chronic Urticaria Index) [<a href="#rid103">103</a>], although the clinical utility of this test is not well established, as discussed in the next section.</p><p class="headingAnchor" id="H1180552"><span class="h4">Conflicting evidence</span><span class="headingEndMark"> — </span>Similar to the ASST, the autoantibodies described above are not specific to CSU. Anti-Fc-epsilon-RI-alpha antibodies have been identified in healthy subjects [<a href="#rid104">104</a>] and in people with other autoimmune diseases, including pemphigus vulgaris, systemic lupus erythematosus, dermatomyositis, and pemphigoid, suggesting that they may represent an epiphenomenon [<a href="#rid98">98,105-107</a>]. In addition, the levels of autoantibodies in CSU do not appear to change with the clinical activity of the disease [<a href="#rid108">108</a>], and the presence of these autoantibodies does not predict more difficult-to-manage disease [<a href="#rid89">89</a>].</p><p>Also problematic is the fact that commercial assays for anti-Fc-epsilon-RI-alpha antibodies are based upon basophil activation tests, for which there are no widely accepted standards across laboratories. When more stringent basophil activation studies were performed with additional controls, only 7 percent of CSU patients were found to have autoantibodies that triggered histamine release, as opposed to the 30 to 50 percent found in earlier studies [<a href="#rid109">109</a>]. The technical difficulties of studying basophils are reviewed below. (See <a class="local">'Problems with basophil studies'</a> below.)</p><p>An effort to better define autoimmune urticaria using multiple assays was undertaken by a European group (Profiling Urticaria for the Identification of Subtypes [PURIST] study) [<a href="#rid90">90</a>]. Using ASST, basophil assays, and enzyme-linked immunosorbent assays (ELISAs), triple-positive patients were defined as true autoimmune urticaria patients and represented 8 percent of subjects. The clinical utility of these findings requires further study.</p><p class="headingAnchor" id="H1180430"><span class="h2">Theories involving other serum or plasma factors</span><span class="headingEndMark"> — </span>Several other factors in the serum or plasma have been implicated in the pathogenesis of CSU because of an ability to activate mast cells or basophils, either directly or indirectly. No single factor has been shown to be essential for a positive ASST, and it remains unclear why serologic factors would activate only skin mast cells rather than causing more generalized mast cell and basophil activation leading to anaphylaxis, yet patients with CSU are not at increased risk for anaphylaxis.</p><p class="bulletIndent1"><span class="glyph">●</span>One study tested sera from patients with CSU and normal controls for the ability to induce endothelial cell permeability [<a href="#rid110">110</a>]. Although neither group's sera alone induced endothelial cell permeability, the majority of CSU sera caused mast cell degranulation when incubated with different mast cell lines, one of which lacked IgE receptors. Supernatants from activated mast cell cultures did increase endothelial cell permeability. This property persisted when the sera were depleted of IgG and was unrelated to the ability of the sera to cause a positive ASST.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The observation that many patients with CSU improve with anti-IgE therapy (<a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>) implies that there may be an abnormal IgE present, which recognizes an unknown antigen(s) and activates mast cells and basophils. Studies of omalizumab for the management of refractory CSU are reviewed separately. A variation on this theory proposes that there are individuals with IgE against self-antigens, but there are limited data for this concept. (See  <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">"Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histamine-releasing factors in the plasma have also been proposed. Some patients with CSU demonstrate excessive or abnormal production of platelet-derived clotting factors, such as thrombin, possibly resulting from activation of the extrinsic pathway of the clotting cascade [<a href="#rid111">111-113</a>]. In one study, the plasma of 28 patients with CSU contained higher levels of the polypeptide F1+2, which is produced upon activation of prothrombin to thrombin, compared with control plasma [<a href="#rid111">111</a>]. The levels of this peptide correlated with the severity of the patients' urticaria. Thrombin, in turn, is capable of activating mast cells and basophils and also increasing the permeability of blood vessels [<a href="#rid114">114-116</a>]. In addition, thrombin can stimulate the generation of C5a, which has been shown to enhance IgG-dependent mast cell histamine release in patients with CSU [<a href="#rid102">102</a>]. Other groups have also found abnormalities in the coagulation system that correlate with CSU severity [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">The identification of abnormalities in clotting factors lead to the autologous plasma skin test (APST), a variant of the ASST in which sodium citrate-anticoagulated plasma is injected intradermally [<a href="#rid111">111</a>]. However, the APST does not appear to provide information that is different from that of the ASST [<a href="#rid111">111,118-120</a>]. Of note, one study showed that if a control solution of 0.105 mol/L sodium citrate was included as a negative control, then there were no patients with positive APSTs who did not also have positive ASSTs [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">The finding that the extrinsic pathway of the clotting cascade is activated in CSU is consistent with reports of successful treatment with the anticoagulant <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in a small double-blind, controlled study, as well as a case report of patients with CSU refractory to antihistamines [<a href="#rid121">121-123</a>]. Subcutaneous heparin and the antifibrinolytic agent <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">tranexamic acid</a> were also reported to be effective in small numbers of patients [<a href="#rid124">124,125</a>].</p><p></p><p>A review examined the literature for serum measures that could distinguish patients with CSU from healthy subjects. Among the measures that showed promise were D-dimer, C-reactive protein (CRP), and mean platelet volume [<a href="#rid126">126</a>]. Although promising, prospective studies will be needed to validate these associations.</p><p class="headingAnchor" id="H20"><span class="h2">Cellular defects theory</span><span class="headingEndMark"> — </span>The cellular defects theory generally proposes that patients with CSU have defects in mast cell and/or basophil trafficking, signaling, and/or function. The following observations support this concept:</p><p class="bulletIndent1"><span class="glyph">●</span>Mast cell numbers are normal in the skin of patients with CSU, although the cells release histamine more readily than cells from healthy controls in response to compounds that trigger nonimmunologic mast cell degranulation, such as 48/80 and <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a> sulfate [<a href="#rid127">127,128</a>]. Functional studies of mast cells from patients with CSU are difficult to perform because mast cells are tissue-based cells that are not easily collected or cultured. In 2015, a G-protein-coupled receptor, Mas-related G protein-coupled receptor X2 (MRGPRX2), was recognized as the receptor for 48/80 on mast cells [<a href="#rid129">129</a>]. It has also been noted that the expression of this receptor is heightened in CSU skin tissue [<a href="#rid130">130</a>] and that skin reactivity to MRGPRX2 ligands is increased in CSU patients as compared with controls [<a href="#rid131">131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood basophil counts are low in patients with CSU and even lower with more severe disease, a finding attributed to increased migration of basophils to the skin [<a href="#rid71">71,132-135</a>]. Evidence supports that basophil counts normalize on therapy with <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid136">136,137</a>]. (See  <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">"Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several groups have identified functional differences in basophils from patients with CSU. Histamine release was reduced following in vitro activation through Fc-epsilon-RI, although not with activation through other receptors [<a href="#rid128">128,138,139</a>], even though the cells contained normal amounts of histamine [<a href="#rid140">140,141</a>]. Subsequently, two basophil phenotypes were identified in patients with CSU: one type with an apparently normal response to Fc-epsilon-RI activation ("responders") and another type of basophil that does not respond to IgE-mediated activation ("nonresponders") [<a href="#rid140">140,142</a>]. These phenotypes are present in approximately equal numbers in patients with CSU, unlike in normals, where "nonresponders" comprise only approximately 10 to 15 percent of the population. The nonresponder phenotype demonstrates elevated intracellular levels of regulatory proteins that normally inhibit signaling through Fc-epsilon-RI. Of note, normalization in basophil responsiveness has been demonstrated in patients with CSU as their symptoms improve, unlike levels of autoantibodies or ASST status [<a href="#rid108">108,139</a>]. CSU patients with the responder phenotype have milder but more prolonged disease [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H1181729"><span class="h3">Problems with basophil studies</span><span class="headingEndMark"> — </span>Basophils are notoriously difficult to study for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Different laboratories using different basophil donors will yield different results with the same tested serum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basophils from individual donors can show variability in response to the same serum over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no standardized procedures for handling basophils for use in serum testing, including uniform approaches to cell isolation, dilution of serum, or addition of a basophil priming cytokine (ie, interleukin [IL] 3) to the assay mix.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Basophils are typically obtained for study from peripheral blood, although it has not been established that circulating basophils are fully representative of cutaneous basophils, and the two populations may have different characteristics in this disorder.</p><p></p><p>Sometimes basophils from normal donors are used to test serum from CSU patients, although histamine release may be due to several factors, such as activated complement, chemokines, or even IL-3 in the tested sample. Thus, the readout of the assay itself represents a complex cellular response that can be elicited through a variety of mechanisms.</p><p class="headingAnchor" id="H1519709"><span class="h2">Other theories</span><span class="headingEndMark"> — </span>Theories about infectious causes and food additives (pseudoallergens) continue to draw periodic attention in the medical literature and lay news. However, the evidence for these theories remains anecdotal. It is possible that various sources of chronic inflammation may predispose susceptible patients to the development of CSU [<a href="#rid143">143</a>].</p><p class="headingAnchor" id="H22"><span class="h3">Infectious agents</span><span class="headingEndMark"> — </span>Attempts have been made to associate some common chronic infections with CSU, including <em>Anisakis simplex</em> [<a href="#rid144">144</a>], <em>Helicobacter pylori</em> [<a href="#rid145">145-148</a>], hepatitis A [<a href="#rid149">149</a>], and hepatitis C [<a href="#rid150">150</a>]. However, case reports and small series have been conflicting [<a href="#rid151">151</a>].</p><p>A larger study illustrated the ambiguous relationship between chronic infections and CSU. In a large meta-analysis of 22 studies including 1385 patients, spontaneous remission of CSU occurred more often in patients who were negative for <em>H. pylori</em> compared with those who were positive (risk ratio 0.39, 95% CI 0.19-0.81) [<a href="#rid152">152</a>]. Among <em>H. pylori</em>-positive CSU patients, remission of urticaria was more likely following antimicrobial therapy for <em>H. pylori</em>, regardless of whether eradication of the infection was successful.</p><p class="headingAnchor" id="H23"><span class="h3">Foods and food additives</span><span class="headingEndMark"> — </span>Allergies to foods or food additives are rarely identified as a cause of CSU [<a href="#rid153">153,154</a>]. IgE-mediated food allergy is far more likely to present with acute urticaria as part of generalized allergic reactions. Despite this, up to one-half of adult patients initially perceive a relationship between food and episodes of urticaria. Patients' suspicion about the role of foods and food additives is fueled by the fact that many will notice that dietary variations can cause temporary fluctuations in CSU symptoms. In particular, rich meals, spicy or fermented foods, alcohol, and dramatic changes in diet will often worsen the condition temporarily. This may be related to the histamine content or innate histamine-releasing properties of these foods, as well as the vasodilatory effects of alcohol and certain spices. However, when CSU is in remission, the same patients can eat these foods without symptoms.</p><p>Dietary factors that can aggravate CSU and lists of foods that are potentially problematic are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Dietary manipulations (controversial)'</a>.)</p><p>Studies of food additives as a cause of acute and chronic urticaria are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/2405.html" rel="external">"Allergic and asthmatic reactions to food additives"</a>.)</p><p class="headingAnchor" id="H1264349"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several systemic disorders can present with urticaria-like lesions in the context of other signs and symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urticarial vasculitis</strong> – Urticarial vasculitis should be considered when the hives are painful rather than pruritic, last longer than 48 hours, leave residual bruising or pigmentation changes, or recur whenever glucocorticoids are tapered  (<a class="graphic graphic_picture graphicRef66203 graphicRef77924 graphicRef54877" href="/z/d/graphic/66203.html" rel="external">picture 2A-C</a>). Patients with urticarial vasculitis may also report fever, chills, and arthralgias. Urticarial vasculitis may occur in isolation or in patients previously diagnosed with other systemic inflammatory diseases, such as Sjögren's disease or systemic lupus erythematosus. Skin biopsy is indicated if signs or symptoms of vasculitis are present. (See  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic lupus erythematosus</strong> – Urticaria and urticarial vasculitis are among the many reported cutaneous manifestations of systemic lupus erythematosus  (<a class="graphic graphic_picture graphicRef55903" href="/z/d/graphic/55903.html" rel="external">picture 3</a>). However, patients with lupus should have some of the other manifestations of this disease, such as fever, weight loss, arthritis, lymphadenopathy, or kidney, pulmonary, or cardiac manifestations. This disorder is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryoglobulinemia</strong> – Cryoglobulinemia causing cold-induced urticarial or vasculitic lesions can be seen in hepatitis B or C infection. Lesions are more prominent on the buttocks and lower extremities. (See  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a> and  <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schnitzler syndrome</strong> – Schnitzler syndrome has been described in patients with a monoclonal immunoglobulin M (IgM) or IgG component (monoclonal gammopathy) who have associated fever, weight loss, bone pain, adenopathy, and urticaria, presumably due to circulating immune complexes and complement activation. (See  <a class="medical medical_review" href="/z/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy"</a> and  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mast cell disorders</strong> – Mast cell disorders are characterized by the proliferation and accumulation of tissue mast cells or excessive activity of these cells. The best-characterized disorders are systemic and cutaneous mastocytosis, which feature signs and symptoms affecting multiple organ systems  (<a class="graphic graphic_table graphicRef91167" href="/z/d/graphic/91167.html" rel="external">table 2</a>). Skin findings in mastocytosis consist either of flushing and pruritus or a distinctive lesion called maculopapular cutaneous mastocytosis or urticaria pigmentosa  (<a class="graphic graphic_picture graphicRef63025" href="/z/d/graphic/63025.html" rel="external">picture 4</a>). Patients with mast cell disorders can have urticaria in the setting of other episodic symptoms, but recurrent hives most days of the week is not typical [<a href="#rid155">155</a>]. Recurrent urticaria, without other systemic signs or symptoms, does not require an evaluation for mast cell disorders. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymorphic eruption of pregnancy</strong> – Polymorphic eruption of pregnancy (PEP; also called pruritic urticarial papules and plaques and papules of pregnancy or PUPPP) is a pruritic dermatitis affecting pregnant females, which typically presents as erythematous papules within abdominal striae with periumbilical sparing  (<a class="graphic graphic_picture graphicRef56116" href="/z/d/graphic/56116.html" rel="external">picture 5</a>). The lesions then spread to the extremities and coalesce to form urticarial plaques. The face, palms, and soles are usually spared. Lesions may also be target like. PEP is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypereosinophilic syndrome</strong> – Hypereosinophilic syndrome refers to a group of disorders characterized by persistent overproduction of eosinophils that infiltrate and damage tissues. Cutaneous symptoms can include recurrent urticaria, although angioedema or erythroderma are more characteristic. The diagnosis requires persistent, unexplained blood eosinophilia of ≥1500/microliter, signs and/or symptoms of eosinophil-mediated end-organ dysfunction, and no other apparent etiologies for eosinophilia, such as parasitic infection or allergic disease. (See  <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">"Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryopyrin-associated periodic syndromes</strong> – The cryopyrin-associated periodic syndromes include syndromes that involve urticarial or urticaria-like skin eruptions: familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disorder. These are rare genetic disorders that are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a>.)</p><p></p><p>Because isolated angioedema is now considered a form of CSU, disorders that present with angioedema (without urticaria) must also be considered in the differential diagnosis. These disorders are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8105.html" rel="external">"An overview of angioedema: Clinical features, diagnosis, and management", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">NATURAL HISTORY AND PROGNOSIS</span></p><p class="headingAnchor" id="H3052791458"><span class="h2">Duration</span><span class="headingEndMark"> — </span>CSU is an episodic and self-limited disorder in most patients. The average duration of disease is two to five years [<a href="#rid3">3,156</a>]. In patients in whom no trigger or underlying disorder is identified, there is a rate of spontaneous remission at one year of approximately 30 to 50 percent [<a href="#rid50">50,157</a>]. Remission rates in children may be somewhat higher [<a href="#rid158">158</a>]. However, symptoms persist beyond five years in up to 30 percent of patients, and disease duration in this subgroup is not as well studied [<a href="#rid11">11,159,160</a>].</p><p class="headingAnchor" id="H310450694"><span class="h2">Factors associated with persistence</span><span class="headingEndMark"> — </span>In a prospective study of 139 patients with CSU of all severity, disease severity, the presence of angioedema, and various laboratory parameters were assessed in relation to disease duration [<a href="#rid159">159</a>]. CSU persisted beyond one and five years in 70 and 14 percent of patients, respectively. A longer duration of symptoms was associated with more severe disease, the presence of angioedema, and thyroid autoimmunity. This study also found that a positive autologous serum skin test was associated with longer-lasting disease, although other studies have not found this correlation [<a href="#rid50">50</a>].</p><p>Other studies have also found that more severe disease tends to last longer [<a href="#rid156">156,158</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of 117 patients with CSU who were not controlled on a standard dose of oral antihistamine, the remission rates (ie, no urticaria for one month in the absence of any medication) were 12 and 28 percent at one and five years, respectively [<a href="#rid158">158</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 228 patients with moderate-to-severe CSU, a correlation was observed between the presence of systemic hypertension and more persistent symptoms [<a href="#rid156">156</a>]. Among hypertensive patients, resolution was seen in 19 and 26 percent at two and five years, respectively, compared with 37 and 46 percent in normotensive patients. The type of antihypertensive medication administered did not appear to impact duration of urticaria. The association with hypertension warrants further study.</p><p></p><p>Peripheral blood eosinopenia and basopenia may be biomarkers for more severe disease that is refractory to antihistamines and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p class="headingAnchor" id="H1069922269"><span class="h2">Impact of pregnancy</span><span class="headingEndMark"> — </span>The impact of pregnancy on CSU and chronic inducible urticaria was examined in an international questionnaire study of 288 pregnancies that found that just over one-half of respondents believed their urticaria improved during pregnancy [<a href="#rid161">161</a>]. The mean duration of chronic urticaria was seven years, and 67 percent of patients had CSU. During pregnancy, 51 percent of patients believed that their symptoms improved, 29 percent that they worsened, and 20 percent reported no change. After giving birth, 44 percent of respondents felt that their disease activity remained unchanged compared with during pregnancy. Patients with more than one pregnancy reported similar changes during each pregnancy.</p><p class="headingAnchor" id="H3118933879"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/108976.html" rel="external">"Society guideline links: Urticaria and angioedema (excluding hereditary angioedema)"</a>.)</p><p class="headingAnchor" id="H357230408"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86634.html" rel="external">"Patient education: Chronic hives (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and prevalence </strong>– Chronic spontaneous urticaria (CSU) is defined by the presence of urticaria (hives), angioedema, or both for a period of six weeks or longer. It is estimated that approximately 1 percent of the adult population develops CSU at some point in their lives. Adults are affected more often than children, and females are affected more often than males. (See <a class="local">'Terminology'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis </strong>– The diagnosis of CSU is made clinically based upon the episodic appearance of characteristic urticarial lesions, with or without angioedema, on most days of the week for a period of six weeks or longer  (<a class="graphic graphic_picture graphicRef89752 graphicRef129552 graphicRef72519 graphicRef129553 graphicRef63644 graphicRef81678 graphicRef77506" href="/z/d/graphic/89752.html" rel="external">picture 1A-G</a>). A complete blood count with differential, a C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and possibly a thyroid-stimulating hormone (TSH) level are suggested at diagnosis, although these laboratories are normal in most patients who lack signs and symptoms of systemic disease. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Skin biopsy is not needed for routine diagnosis of CSU, although it is indicated to exclude urticarial vasculitis if there are signs or symptoms consistent with a vasculitic process  (<a class="graphic graphic_picture graphicRef66203 graphicRef77924 graphicRef54877" href="/z/d/graphic/66203.html" rel="external">picture 2A-C</a>), or in the rare patients with features of mastocytosis. (See <a class="local">'Skin biopsy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tests used in investigations of pathogenesis include the autologous serum and plasma skin tests (ASST/APST), assays for autoantibodies directed against immunoglobulin E (IgE) or Fc-epsilon-RI, and in vitro assessments of basophil function. However, these tests lack specificity and prognostic value, are not standardized across laboratories, and are not recommended for routine clinical use. (See <a class="local">'Theories of pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– No specific trigger or etiology can be identified in 80 to 90 percent of adults and children with CSU if a careful history does not suggest one, although patients may be able to identify factors that aggravate the disorder once it is present  (<a class="graphic graphic_table graphicRef98751" href="/z/d/graphic/98751.html" rel="external">table 1</a>). Several theories regarding the pathogenesis have been proposed, although the data for each are incomplete, and none appear to be helpful for determining treatment or prognosis. The best developed hypotheses involve histamine-releasing factors and defects in basophil signaling and/or function. (See <a class="local">'Theories of pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history and prognosis </strong>– CSU is a self-limited disease in the vast majority of patients. Spontaneous remission occurs in 30 to 50 percent of adults by one year, and the average duration of disorder is two to five years. Average disease duration is shorter in children. Up to 20 percent of adults still have symptoms persisting beyond five years. Those with more severe symptoms initially tend to have longer-lasting disease. (See <a class="local">'Natural history and prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77:734.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73:1393.</a></li><li><a class="nounderline abstract_t">Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105:664.</a></li><li><a class="nounderline abstract_t">Gaig P, Olona M, Muñoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14:214.</a></li><li><a class="nounderline abstract_t">Lapi F, Cassano N, Pegoraro V, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol 2016; 174:996.</a></li><li><a class="nounderline abstract_t">Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol 2021; 184:226.</a></li><li><a class="nounderline abstract_t">Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy 2020; 75:423.</a></li><li><a class="nounderline abstract_t">Confino-Cohen R, Chodick G, Shalev V, et al. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol 2012; 129:1307.</a></li><li><a class="nounderline abstract_t">Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2009; 103:496.</a></li><li><a class="nounderline abstract_t">Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005. J Investig Allergol Clin Immunol 2009; 19 Suppl 2:21.</a></li><li><a class="nounderline abstract_t">Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969; 81:588.</a></li><li><a class="nounderline abstract_t">Hellgren L. The prevalence of urticaria in the total population. Acta Allergol 1972; 27:236.</a></li><li><a class="nounderline abstract_t">Juhlin L. Recurrent urticaria: clinical investigation of 330 patients. Br J Dermatol 1981; 104:369.</a></li><li><a class="nounderline abstract_t">Buss YA, Garrelfs UC, Sticherling M. Chronic urticaria--which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. J Dtsch Dermatol Ges 2007; 5:22.</a></li><li><a class="nounderline abstract_t">Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.</a></li><li><a class="nounderline abstract_t">Doong JC, Chichester K, Oliver ET, et al. Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures. J Allergy Clin Immunol Pract 2017; 5:1314.</a></li><li><a class="nounderline abstract_t">Sabroe RA, Seed PT, Francis DM, et al. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40:443.</a></li><li><a class="nounderline abstract_t">Özçeker D, Can PK, Terzi Ö, et al. Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response. Pediatr Allergy Immunol 2023; 34:e13925.</a></li><li><a class="nounderline abstract_t">O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197.</a></li><li><a class="nounderline abstract_t">Rossi O, Piccirillo A, Iemoli E, et al. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study. World Allergy Organ J 2020; 13:100470.</a></li><li><a class="nounderline abstract_t">Al-Ahmad M, Alowayesh MS, Carroll NV. Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system. Clinicoecon Outcomes Res 2016; 8:163.</a></li><li><a class="nounderline abstract_t">Matsubara D, Takahagi S, Saito R, et al. Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. J Dermatol 2021; 48:56.</a></li><li><a class="nounderline abstract_t">Rosman Y, Hershko AY, Meir-Shafrir K, et al. Characterization of chronic urticaria and associated conditions in a large population of adolescents. J Am Acad Dermatol 2019; 81:129.</a></li><li><a class="nounderline abstract_t">Kozel MM, Bossuyt PM, Mekkes JR, Bos JD. Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol 2003; 48:409.</a></li><li><a class="nounderline abstract_t">Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84:66.</a></li><li><a class="nounderline abstract_t">Dreskin SC, Andrews KY. The thyroid and urticaria. Curr Opin Allergy Clin Immunol 2005; 5:408.</a></li><li><a class="nounderline abstract_t">Caffarelli C, Cuomo B, Cardinale F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta Derm Venereol 2013; 93:268.</a></li><li><a class="nounderline abstract_t">Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review. Autoimmun Rev 2017; 16:1196.</a></li><li><a class="nounderline abstract_t">Kim YS, Han K, Lee JH, et al. Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study. Allergy Asthma Immunol Res 2017; 9:373.</a></li><li><a class="nounderline abstract_t">Leznoff A, Josse RG, Denburg J, Dolovich J. Association of chronic urticaria and angioedema with thyroid autoimmunity. Arch Dermatol 1983; 119:636.</a></li><li><a class="nounderline abstract_t">Kaplan AP, Finn A. Autoimmunity and the etiology of chronic urticaria. Can J Allergy Clin Immunol 1999; 4:286.</a></li><li><a class="nounderline abstract_t">Kikuchi Y, Fann T, Kaplan AP. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 2003; 112:218.</a></li><li><a class="nounderline abstract_t">Tienforti D, Di Giulio F, Spagnolo L, et al. Chronic urticaria and thyroid autoimmunity: a meta-analysis of case-control studies. J Endocrinol Invest 2022; 45:1317.</a></li><li><a class="nounderline abstract_t">Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy 2017; 72:1440.</a></li><li><a class="nounderline abstract_t">Powell RJ, Du Toit GL, Siddique N, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007; 37:631.</a></li><li><a class="nounderline abstract_t">Tedeschi A, Girolomoni G, Asero R, AAITO Committee for Chronic Urticaria and Pruritus Guidelines. AAITO Position paper. Chronic urticaria: diagnostic workup and treatment. Eur Ann Allergy Clin Immunol 2007; 39:225.</a></li><li><a class="nounderline abstract_t">Lindelöf B, Sigurgeirsson B, Wahlgren CF, Eklund G. Chronic urticaria and cancer: an epidemiological study of 1155 patients. Br J Dermatol 1990; 123:453.</a></li><li><a class="nounderline abstract_t">Chen YJ, Wu CY, Shen JL, et al. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol 2012; 148:103.</a></li><li><a class="nounderline abstract_t">Larenas-Linnemann D, Saini SS, Azamar-Jácome AA, Maurer M. Chronic urticaria can be caused by cancer and resolves with its cure. Allergy 2018; 73:1562.</a></li><li><a class="nounderline abstract_t">Charlesworth EN. The spectrum of urticaria: All that urticates may not be urticaria. Immunol Allergy Clin North Am 1995; 15:641.</a></li><li><a class="nounderline abstract_t">Beltrani VS. Urticaria and angioedema. Dermatol Clin 1996; 14:171.</a></li><li><a class="nounderline abstract_t">Charlesworth EN. Urticaria and angioedema: a clinical spectrum. Ann Allergy Asthma Immunol 1996; 76:484.</a></li><li><a class="nounderline abstract_t">Beltrani VS. Urticaria: reassessed. Allergy Asthma Proc 2004; 25:143.</a></li><li><a class="nounderline abstract_t">Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64:1417.</a></li><li><a class="nounderline abstract_t">deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895.</a></li><li><a class="nounderline abstract_t">Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002; 89:542.</a></li><li><a class="nounderline abstract_t">Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol 2005; 5:403.</a></li><li><a class="nounderline abstract_t">Harris A, Twarog FJ, Geha RS. Chronic urticaria in childhood: natural course and etiology. Ann Allergy 1983; 51:161.</a></li><li><a class="nounderline abstract_t">Kulthanan K, Jiamton S, Thumpimukvatana N, Pinkaew S. Chronic idiopathic urticaria: prevalence and clinical course. J Dermatol 2007; 34:294.</a></li><li><a class="nounderline abstract_t">Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104:169.</a></li><li><a class="nounderline abstract_t">Laman SD, Provost TT. Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20:195.</a></li><li><a class="nounderline abstract_t">Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28:123.</a></li><li><a class="nounderline abstract_t">Hunkin V, Chung MC. Chronic idiopathic urticaria, psychological co-morbidity and posttraumatic stress: the impact of alexithymia and repression. Psychiatr Q 2012; 83:431.</a></li><li><a class="nounderline abstract_t">Staubach P, Dechene M, Metz M, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol 2011; 91:557.</a></li><li><a class="nounderline abstract_t">Chung MC, Symons C, Gilliam J, Kaminski ER. The relationship between posttraumatic stress disorder, psychiatric comorbidity, and personality traits among patients with chronic idiopathic urticaria. Compr Psychiatry 2010; 51:55.</a></li><li><a class="nounderline abstract_t">Malhotra SK, Mehta V. Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria. Indian J Dermatol Venereol Leprol 2008; 74:594.</a></li><li><a class="nounderline abstract_t">Kimyai-Asadi A, Usman A. The role of psychological stress in skin disease. J Cutan Med Surg 2001; 5:140.</a></li><li><a class="nounderline abstract_t">Ozkan M, Oflaz SB, Kocaman N, et al. Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2007; 99:29.</a></li><li><a class="nounderline abstract_t">Chung MC, Symons C, Gilliam J, Kaminski ER. Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria. Psychol Health 2010; 25:477.</a></li><li><a class="nounderline abstract_t">Hergüner S, Kiliç G, Karakoç S, et al. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol 2011; 164:1342.</a></li><li><a class="nounderline abstract_t">Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy 2013; 68:131.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427.</a></li><li><a class="nounderline abstract_t">Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134:1575.</a></li><li><a class="nounderline abstract_t">Jacobson KW, Branch LB, Nelson HS. Laboratory tests in chronic urticaria. JAMA 1980; 243:1644.</a></li><li><a class="nounderline abstract_t">Lang DM. Evidence-based diagnosis and treatment of chronic urticaria/angioedema. Allergy Asthma Proc 2014; 35:10.</a></li><li><a class="nounderline abstract_t">Maurer M, Magerl M, Metz M, Zuberbier T. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges 2013; 11:971.</a></li><li><a class="nounderline abstract_t">Hide M, Hiragun T, Japanese Dermatological Association. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int 2012; 61:517.</a></li><li><a class="nounderline abstract_t">Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. J Allergy Clin Immunol Pract 2020; 8:318.</a></li><li><a class="nounderline abstract_t">Shah AD, Denaxas S, Nicholas O, et al. Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases: a CALIBER cohort study. Open Heart 2016; 3:e000477.</a></li><li><a class="nounderline abstract_t">Huang AH, Chichester KL, Saini SS. Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU). J Allergy Clin Immunol Pract 2020; 8:793.</a></li><li><a class="nounderline abstract_t">Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy 2018; 73:940.</a></li><li><a class="nounderline abstract_t">Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.</a></li><li><a class="nounderline abstract_t">Jirapongsananuruk O, Pongpreuksa S, Sangacharoenkit P, et al. Identification of the etiologies of chronic urticaria in children: a prospective study of 94 patients. Pediatr Allergy Immunol 2010; 21:508.</a></li><li><a class="nounderline abstract_t">Zuberbier T. Urticaria. Allergy 2003; 58:1224.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Fraga J, Requena L, et al. [Neutrophilic urticaria or urticaria with predominantly neutrophilic inflammatory infiltrate: study of its clinical and histopathologic characteristics and its possible association with rheumatic disease]. Actas Dermosifiliogr 2012; 103:511.</a></li><li><a class="nounderline abstract_t">Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008; 20:709.</a></li><li><a class="nounderline abstract_t">Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol 2019; 10:627.</a></li><li><a class="nounderline abstract_t">Konstantinou GN, Asero R, Ferrer M, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68:27.</a></li><li><a class="nounderline abstract_t">Grattan CE, Wallington TB, Warin RP, et al. A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114:583.</a></li><li><a class="nounderline abstract_t">Grattan CE, Hamon CG, Cowan MA, Leeming RJ. Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria. Br J Dermatol 1988; 119:179.</a></li><li><a class="nounderline abstract_t">Sabroe RA, Grattan CE, Francis DM, et al. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140:446.</a></li><li><a class="nounderline abstract_t">Mari A. Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test. Int Arch Allergy Immunol 2004; 133:29.</a></li><li><a class="nounderline abstract_t">Guttman-Yassky E, Bergman R, Maor C, et al. The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals. J Eur Acad Dermatol Venereol 2007; 21:35.</a></li><li><a class="nounderline abstract_t">Taskapan O, Kutlu A, Karabudak O. Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/non-allergic asthma or rhinitis and healthy people. Clin Exp Dermatol 2008; 33:754.</a></li><li><a class="nounderline abstract_t">Fagiolo U, Kricek F, Ruf C, et al. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106:567.</a></li><li><a class="nounderline abstract_t">Fusari A, Colangelo C, Bonifazi F, Antonicelli L. The autologous serum skin test in the follow-up of patients with chronic urticaria. Allergy 2005; 60:256.</a></li><li><a class="nounderline abstract_t">Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162:191.</a></li><li><a class="nounderline abstract_t">Lapolla W, Desai N, English JC 3rd. Clinical utility of testing for autoimmunity in chronic idiopathic urticaria. J Am Acad Dermatol 2012; 66:e83.</a></li><li><a class="nounderline abstract_t">Schoepke N, Asero R, Ellrich A, et al. Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. Allergy 2019; 74:2427.</a></li><li><a class="nounderline abstract_t">Gruber BL, Baeza ML, Marchese MJ, et al. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90:213.</a></li><li><a class="nounderline abstract_t">Sabroe RA, Greaves MW. Chronic idiopathic urticaria with functional autoantibodies: 12 years on. Br J Dermatol 2006; 154:813.</a></li><li><a class="nounderline abstract_t">Tong LJ, Balakrishnan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99:461.</a></li><li><a class="nounderline abstract_t">Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599.</a></li><li><a class="nounderline abstract_t">Niimi N, Francis DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 1996; 106:1001.</a></li><li><a class="nounderline abstract_t">Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96:2606.</a></li><li><a class="nounderline abstract_t">Brunetti L, Francavilla R, Miniello VL, et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114:922.</a></li><li><a class="nounderline abstract_t">Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998; 101:243.</a></li><li><a class="nounderline abstract_t">Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115:815.</a></li><li><a class="nounderline abstract_t">Zweiman B, Valenzano M, Atkins PC, et al. Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria. J Allergy Clin Immunol 1996; 98:89.</a></li><li><a class="nounderline abstract_t">Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107:1056.</a></li><li><a class="nounderline abstract_t">Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109:114.</a></li><li class="breakAll">The CU index test is available commercially. www.viracoribt.com (Accessed on April 12, 2012).</li><li><a class="nounderline abstract_t">Eckman JA, Hamilton RG, Saini SS. Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects. J Invest Dermatol 2009; 129:1584.</a></li><li><a class="nounderline abstract_t">Horn MP, Pachlopnik JM, Vogel M, et al. Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies? FASEB J 2001; 15:2268.</a></li><li><a class="nounderline abstract_t">Vasagar K, Vonakis BM, Gober LM, et al. Evidence of in vivo basophil activation in chronic idiopathic urticaria. Clin Exp Allergy 2006; 36:770.</a></li><li><a class="nounderline abstract_t">Cho CB, Stutes SA, Altrich ML, et al. Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders. Ann Allergy Asthma Immunol 2013; 110:29.</a></li><li><a class="nounderline abstract_t">Eckman JA, Hamilton RG, Gober LM, et al. Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies. J Invest Dermatol 2008; 128:1956.</a></li><li><a class="nounderline abstract_t">MacGlashan D. Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils. J Allergy Clin Immunol 2019; 143:1100.</a></li><li><a class="nounderline abstract_t">Bossi F, Frossi B, Radillo O, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; 66:1538.</a></li><li><a class="nounderline abstract_t">Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117:1113.</a></li><li><a class="nounderline abstract_t">Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119:705.</a></li><li><a class="nounderline abstract_t">Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65:649.</a></li><li><a class="nounderline abstract_t">Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133:3282.</a></li><li><a class="nounderline abstract_t">Vliagoftis H. Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1. J Immunol 2002; 169:4551.</a></li><li><a class="nounderline abstract_t">Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.</a></li><li><a class="nounderline abstract_t">Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66:428.</a></li><li><a class="nounderline abstract_t">Sajedi V, Movahedi M, Aghamohammadi A, et al. Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (FcεRIα). Iran J Allergy Asthma Immunol 2011; 10:111.</a></li><li><a class="nounderline abstract_t">Kocatürk E, Kavala M, Kural E, et al. Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies. Eur J Dermatol 2011; 21:339.</a></li><li><a class="nounderline abstract_t">Yıldız H, Karabudak O, Doğan B, Harmanyeri Y. Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria. Br J Dermatol 2011; 165:1205.</a></li><li><a class="nounderline abstract_t">Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30:1161.</a></li><li><a class="nounderline abstract_t">Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75:187.</a></li><li><a class="nounderline abstract_t">Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010; 5:97.</a></li><li><a class="nounderline abstract_t">Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153:216.</a></li><li><a class="nounderline abstract_t">Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152:384.</a></li><li><a class="nounderline abstract_t">Kolkhir P, André F, Church MK, et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy 2017; 47:19.</a></li><li><a class="nounderline abstract_t">Jacques P, Lavoie A, Bédard PM, et al. Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission. J Allergy Clin Immunol 1992; 89:1139.</a></li><li><a class="nounderline abstract_t">Cohen RW, Rosenstreich DL. Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine. J Allergy Clin Immunol 1986; 77:802.</a></li><li><a class="nounderline abstract_t">McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 2015; 519:237.</a></li><li><a class="nounderline abstract_t">Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol 2014; 134:622.</a></li><li><a class="nounderline abstract_t">Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria. J Invest Dermatol 2021; 141:678.</a></li><li><a class="nounderline abstract_t">Grattan CE, Walpole D, Francis DM, et al. Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity. Clin Exp Allergy 1997; 27:1417.</a></li><li><a class="nounderline abstract_t">Grattan CE, Dawn G, Gibbs S, Francis DM. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy 2003; 33:337.</a></li><li><a class="nounderline abstract_t">Caproni M, Giomi B, Volpi W, et al. Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals. Clin Immunol 2005; 114:284.</a></li><li><a class="nounderline abstract_t">Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694.</a></li><li><a class="nounderline abstract_t">Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72:519.</a></li><li><a class="nounderline abstract_t">Saini SS, Omachi TA, Trzaskoma B, et al. Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria. J Invest Dermatol 2017; 137:958.</a></li><li><a class="nounderline abstract_t">Greaves MW, Plummer VM, McLaughlan P, Stanworth DR. Serum and cell bound IgE in chronic urticaria. Clin Allergy 1974; 4:265.</a></li><li><a class="nounderline abstract_t">Kern F, Lichtenstein LM. Defective histamine release in chronic urticaria. J Clin Invest 1976; 57:1369.</a></li><li><a class="nounderline abstract_t">Vonakis BM, Vasagar K, Gibbons SP Jr, et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. J Allergy Clin Immunol 2007; 119:441.</a></li><li><a class="nounderline abstract_t">Sabroe RA, Francis DM, Barr RM, et al. Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria. J Allergy Clin Immunol 1998; 102:651.</a></li><li><a class="nounderline abstract_t">Rauber MM, Pickert J, Holiangu L, et al. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy 2017; 72:1904.</a></li><li><a class="nounderline abstract_t">Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol 2019; 15:56.</a></li><li><a class="nounderline abstract_t">Ventura MT, Napolitano S, Menga R, et al. Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas. Int Arch Allergy Immunol 2013; 160:297.</a></li><li><a class="nounderline abstract_t">Liutu M, Kalimo K, Uksila J, Kalimo H. Etiologic aspects of chronic urticaria. Int J Dermatol 1998; 37:515.</a></li><li><a class="nounderline abstract_t">Di Campli C, Gasbarrini A, Nucera E, et al. Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria. Dig Dis Sci 1998; 43:1226.</a></li><li><a class="nounderline abstract_t">Başkan EB, Türker T, Gülten M, Tunali S. Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria. Int J Dermatol 2005; 44:993.</a></li><li><a class="nounderline abstract_t">Schnyder B, Helbling A, Pichler WJ. Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection. Int Arch Allergy Immunol 1999; 119:60.</a></li><li><a class="nounderline abstract_t">Wedi B, Raap U, Kapp A. Chronic urticaria and infections. Curr Opin Allergy Clin Immunol 2004; 4:387.</a></li><li><a class="nounderline abstract_t">Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995; 70:559.</a></li><li><a class="nounderline abstract_t">Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol 2010; 10:362.</a></li><li><a class="nounderline abstract_t">Kim HJ, Kim YJ, Lee HJ, et al. Systematic review and meta-analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria. Helicobacter 2019; 24:e12661.</a></li><li><a class="nounderline abstract_t">Chung BY, Cho YS, Kim HO, Park CW. Food Allergy in Korean Patients with Chronic Urticaria. Ann Dermatol 2016; 28:562.</a></li><li><a class="nounderline abstract_t">Hsu ML, Li LF. Prevalence of food avoidance and food allergy in Chinese patients with chronic urticaria. Br J Dermatol 2012; 166:747.</a></li><li><a class="nounderline abstract_t">Siles R, Xu M, Hsieh FH. The utility of serum tryptase as a marker in chronic spontaneous urticaria. Acta Derm Venereol 2013; 93:354.</a></li><li><a class="nounderline abstract_t">Nebiolo F, Bergia R, Bommarito L, et al. Effect of arterial hypertension on chronic urticaria duration. Ann Allergy Asthma Immunol 2009; 103:407.</a></li><li><a class="nounderline abstract_t">Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001; 45:387.</a></li><li><a class="nounderline abstract_t">Hiragun M, Hiragun T, Mihara S, et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 2013; 68:229.</a></li><li><a class="nounderline abstract_t">Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004; 59:869.</a></li><li><a class="nounderline abstract_t">van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002; 146:110.</a></li><li><a class="nounderline abstract_t">Kocatürk E, Al-Ahmad M, Krause K, et al. Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study. Allergy 2021; 76:3133.</a></li></ol></div><div id="topicVersionRevision">Topic 8108 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34536239" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29336054" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10756214" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552715" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of urticaria in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26872037" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956489" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The global burden of chronic urticaria for the patient and society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31494963" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336078" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic urticaria and autoimmunity: associations found in a large population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20084843" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19530414" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5801331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Urticaria and angio-oedema. A review of 554 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4678809" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The prevalence of urticaria in the total population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7236502" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Recurrent urticaria: clinical investigation of 330 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229201" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic urticaria--which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356542" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Chronic urticaria: pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28302451" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071316" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36825740" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068731" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of chronic urticaria on the quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33343800" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27274290" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33029864" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30797847" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characterization of chronic urticaria and associated conditions in a large population of adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637921" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754146" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131915" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The thyroid and urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23224228" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aetiological factors associated with chronic urticaria in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29037900" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28497925" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6870316" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Association of chronic urticaria and angioedema with thyroid autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Autoimmunity and the etiology of chronic urticaria</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847508" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antithyroid antibodies in chronic urticaria and angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35181847" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chronic urticaria and thyroid autoimmunity: a meta-analysis of case-control studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28407273" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456211" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : BSACI guidelines for the management of chronic urticaria and angio-oedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18236998" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : AAITO Position paper. Chronic urticaria: diagnostic workup and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2095176" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic urticaria and cancer: an epidemiological study of 1155 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250240" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cancer risk in patients with chronic urticaria: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29517800" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chronic urticaria can be caused by cancer and resolves with its cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The spectrum of urticaria: All that urticates may not be urticaria</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821171" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Urticaria and angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8673682" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Urticaria and angioedema: a clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15317316" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Urticaria: reassessed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24766875" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The diagnosis and management of acute and chronic urticaria: 2014 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772512" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396651" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Allergic reactions to drugs and biologic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487218" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Sensitivity to nonsteroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131914" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6881605" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic urticaria in childhood: natural course and etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408437" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Chronic idiopathic urticaria: prevalence and clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400855" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Complement dependence of histamine release in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8153399" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cutaneous manifestations of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12653694" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Aspirin sensitivity and urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362490" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Chronic idiopathic urticaria, psychological co-morbidity and posttraumatic stress: the impact of alexithymia and repression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21597672" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19932827" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The relationship between posttraumatic stress disorder, psychiatric comorbidity, and personality traits among patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171981" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443487" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The role of psychological stress in skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17650826" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204926" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083542" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157275" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Psychosocial factors and chronic spontaneous urticaria: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772513" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875196" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7359752" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Laboratory tests in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24433592" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evidence-based diagnosis and treatment of chronic urticaria/angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034140" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23093797" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31472293" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27621833" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases: a CALIBER cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31421279" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Association of basophil parameters with disease severity and duration in chronic spontaneous urticaria (CSU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29130488" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796852" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical practice. Chronic urticaria and angioedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19555353" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Identification of the etiologies of chronic urticaria in children: a prospective study of 94 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616095" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22475309" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : [Neutrophilic urticaria or urticaria with predominantly neutrophilic inflammatory infiltrate: study of its clinical and histopathologic characteristics and its possible association with rheumatic disease].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832031" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : New concepts in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30984191" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Autoimmune Theories of Chronic Spontaneous Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157716" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3718848" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A serological mediator in chronic idiopathic urticaria--a clinical, immunological and histological evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3166939" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Preliminary identification of a low molecular weight serological mediator in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233264" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14646376" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Allergy-like asthma and rhinitis. A cross-sectional survey of a respiratory cohort and a diagnostic approach using the autologous serum skin test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207165" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18954415" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Evaluation of autologous serum skin test results in patients with chronic idiopathic urticaria, allergic/non-allergic asthma or rhinitis and healthy people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10984379" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647050" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The autologous serum skin test in the follow-up of patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903174" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565421" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical utility of testing for autoimmunity in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31228881" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2448392" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634880" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chronic idiopathic urticaria with functional autoantibodies: 12 years on.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9111489" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Assessment of autoimmunity in patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683772" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618029" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675625" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480336" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : High prevalence of autoimmune urticaria in children with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9421487" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806004" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765822" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Characteristics of histamine-releasing activity in the sera of patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398085" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Mechanisms of autoimmune activation of basophils in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11799375" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11799375" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131947" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Independent evaluation of a commercial test for "autoimmune" urticaria in normal and chronic urticaria subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641254" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16776678" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Evidence of in vivo basophil activation in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23244655" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Autoantibodies in chronic idiopathic urticaria and nonurticarial systemic autoimmune disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18356810" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29859965" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906078" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16675340" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17204316" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845571" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208276" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Thrombin-induced degranulation of cultured bone marrow-derived mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12370392" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16715088" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Generation of C5a in the absence of C3: a new complement activation pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083568" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Increase of coagulation potential in chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21625019" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Comparison between sensitivity of autologous skin serum test and autologous plasma skin test in patients with Chronic Idiopathic Urticaria for detection of antibody against IgE or IgE receptor (FcεRIα).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697031" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910697" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931124" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Warfarin treatment of chronic idiopathic urticaria and angio-oedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293513" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of warfarin on chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949893" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16029359" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Chronic urticaria responding to subcutaneous heparin sodium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20203527" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27926978" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Potential blood biomarkers in chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1376735" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Chronic idiopathic urticaria: profiles of skin mast cell histamine release during active disease and remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3711548" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517090" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954276" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32771471" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9433937" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Flow cytometric analysis of basophil numbers in chronic urticaria: basopenia is related to serum histamine releasing activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614448" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721839" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Chronic idiopathic urticaria: infiltrating cells and related cytokines in autologous serum-induced wheals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941321" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861988" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27939380" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4473279" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Serum and cell bound IgE in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/57121" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Defective histamine release in chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17125820" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802375" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Anti-Fc(episilon)RI auto antibodies and basophil histamine releasability in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28585360" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31528163" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095317" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Anisakis simplex hypersensitivity is associated with chronic urticaria in endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9679692" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Etiologic aspects of chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635612" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Beneficial effects of Helicobacter pylori eradication on idiopathic chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16409261" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Lack of correlation between Helicobacter pylori infection and autologous serum skin test in chronic idiopathic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10341322" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349038" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Chronic urticaria and infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776716" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Chronic hepatitis C and skin diseases: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610979" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31523897" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Systematic review and meta-analysis: Effect of Helicobacter pylori eradication on chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27746634" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Food Allergy in Korean Patients with Chronic Urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092280" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Prevalence of food avoidance and food allergy in Chinese patients with chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165773" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : The utility of serum tryptase as a marker in chronic spontaneous urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19927539" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Effect of arterial hypertension on chronic urticaria duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511835" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Natural course of physical and chronic urticaria and angioedema in 220 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205732" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15230821" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11841375" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34022061" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
